0
Please log in or register to do it.

Y Biologics-Vaxell Bio, antibody sequence technology transfer agreement

Y Biologics-Vaxell Bio, antibody sequence technology transfer agreement

(Seoul = Larose.VIP) Reporter Kim Hyun-soo = YBiologics, an antibody drug development platform company[338840]Vaxcell Bio, an anti-cancer immune cell therapy development company[323990]announced on the 14th that it had signed a technology transfer agreement for the sequence of anti-PD-L1 (a protein on the surface of cancer cells) antibody ‘YBL-007’.

An antibody sequence refers to a ‘blueprint’ that represents the unique characteristics of an antibody.

According to the contract, Vaxcell Bio has the license to research, develop and commercialize CAR-T (chimeric antigen receptor T cell) or CAR-NK (chimeric antigen receptor natural killer cell) treatments using the YBL-007 sequence. .

According to Y Biologics, this contract was carried out in accordance with the two companies’ joint research on next-generation anti-cancer cell therapy.

Park Young-woo, CEO of Y Biologics, said, “As a result of cooperation between antibody and cell therapy development companies, we have achieved the result of technology transfer,” and added, “We will strive to accumulate references that can create synergy between various biopharmaceuticals and antibodies.”

hyunsu@yna.co.kr

Report to KakaoTalk okjebo 2024/02/14 12:44 Sent

Hint of imminent iQoo Z9 BIS listing
Pastor Younghoon Lee of Yoido Full Gospel Church, “Let’s introduce cognitive sensitivity in parenting.”

Reactions

0
0
0
0
0
0
Already reacted for this post.

Reactions

Your email address will not be published. Required fields are marked *